Takeda Reveals Encouraging Initial Outcomes of Phase 2 Trial for Mezagitamab (TAK-079), an Emerging Leading Anti-CD38 Monoclonal Antibody, in Treating Primary Immune Thrombocytopenia.
Doxepin, the small molecule drug, serves as a cogent therapeutic agent, targeting both the norepinephrine transporter (NET) and serotonin transporter subtype 5 (SERT-5).
clinical-stage biopharma atai Life Sciences (NASDAQ: ATAI), focused on transforming mental health treatment, announced a strategic investment in Beckley Psytech, cementing its position as the bio-pharma leader with the broadest portfolio of clinical-stage psychedelic drug candidates.
Recently, a collaborative research effort involving multiple German scientific institutions has revealed that the endothelin B receptor (ETB) plays a crucial role in controlling metabolic syndrome brought on by high-calorie diets.
Simvastatin, a diminutive molecular entity, functions as an HMG-CoA reductase enzyme inhibitor, which is accountable for the synthesis of cholesterol in the hepatic tissue.
Johnson & Johnson has filed a supplementary application with the FDA for the authorization of TREMFYA® (guselkumab) aimed at treating moderate to severe ulcerative colitis in adults.
Bispecific antibodies (bsAbs) possess unique advantages due to their ability to simultaneously target two distinct antigens, which helps to enhance the immune system's recognition and killing of tumor cells.